A Phase III Study of Surgery in Combination With Neoadjuvant Chemotherapy of Oxaliplatin Plus Capecitabine in Colorectal Cancer With Respectable Liver Metastasis
Liver metastasis is the most important prognostic factor of colorectal cancer. Reasonable
multidisciplinary therapy might improve the prognosis of patients with liver metastasis.
Surgery has been the first choice under such situation. Recently, neoadjuvant chemotherapy
has also shown its value in unresectable liver metastasis, for it can increase the chance of
R0 resection and give some clues to chemosensitivity of agents. However, for those
resectable lesions, the role and safety of neoadjuvant chemotherapy has yet to be confirmed.
so we design this study.
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
disease free survival rate
Shan Wang, MD
Peking University People's Hospital, Department of General Surgery
China: Food and Drug Administration